$123.82
7.23% yesterday
Nasdaq, Nov 20, 10:00 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$123.82
+3.92 3.27% 1M
-0.89 0.71% 6M
+61.47 98.59% YTD
+46.62 60.39% 1Y
+66.10 114.52% 3Y
+109.04 737.75% 5Y
+107.82 673.88% 10Y
+107.82 673.88% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-9.65 7.23%

New AI Insights on TransMedics Group, Inc. Insights AI Insights on TransMedics Group, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$4.3b
Net debt
$45.8m
Cash
$466.2m
Shares outstanding
34.0m
Valuation (TTM | estimate)
P/E
55.3 | 46.8
P/S
7.5 | 6.9
EV/Sales
7.6 | 7.0
EV/FCF
35.6
P/B
11.9
Financial Health
Equity Ratio
28.5%
Return on Equity
15.3%
ROCE
11.0%
ROIC
20.3%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$566.4m | $613.0m
EBITDA
$95.9m | $139.2m
EBIT
$95.6m | $96.5m
Net Income
$91.9m | $90.0m
Free Cash Flow
$120.0m
Growth (TTM | estimate)
Revenue
41.2% | 38.8%
EBITDA
202.2% | 274.3%
EBIT
204.1% | 160.8%
Net Income
181.4% | 157.1%
Free Cash Flow
199.6%
Margin (TTM | estimate)
Gross
60.3%
EBITDA
16.9% | 22.7%
EBIT
16.9%
Net
16.2% | 14.7%
Free Cash Flow
21.2%
More
EPS
$2.2
FCF per Share
$3.5
Short interest
37.9%
Employees
728
Rev per Employee
$610.0k
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a TransMedics Group, Inc. forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
79%
Hold
21%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
566 566
41% 41%
100%
- Direct Costs 225 225
38% 38%
40%
341 341
43% 43%
60%
- Selling and Administrative Expenses 181 181
16% 16%
32%
- Research and Development Expense 65 65
29% 29%
11%
96 96
202% 202%
17%
- Depreciation and Amortization 0.30 0.30
0% 0%
0%
EBIT (Operating Income) EBIT 96 96
204% 204%
17%
Net Profit 92 92
181% 181%
16%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
PRNewsWire
2 days ago
ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference at the ...
Positive
The Motley Fool
8 days ago
The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.
Positive
Seeking Alpha
15 days ago
During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical role in delivering clean, reliable, 'always on' power at scale. Oddity Tech is a digital beauty and wellness platform that uses AI and data science to develop and recommend personalized products base...
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today